No clinical study data is present in the provided text, which consists only of journal editorial board information.
Can the endogenous thrombin potential (ETP) be routinely measured to assess different forms of hyper- and hypocoagulability?
The endogenous thrombin potential can be routinely measured using a centrifugal analyser and effectively reflects both hypercoagulable states (such as DVT and CAD) and hypocoagulable states (such as anticoagulant therapy).
The area under the thrombin generation curve (the endogenous thrombin potential; ETP) has been proposed as a parameter for plasma-based hypercoagulability and to monitor anticoagulant treatment. We present an ETP assay for the routine laboratory using a centrifugal analyser. Throughput is 30 samples/h, within and between run imprecision is 4-5.6%. Suitable substrates were developed for the ranges of 10-500% and 2-100% of normal. Independent of tissue factor concentration (if > 4 pM), the normal value of the extrinsic ETP is 384.8 +/- 51.7 nM.min. The intrinsic ETP, triggered by ellagic acid, is 414 +/- 41 nM.min. The ETP is decreased to 15 and 35% of normal by oral anticoagulation (INR 2.5-4.0) and by heparin administration (APTT 1.5-2.5 x control). The ETP is increased in untreated subjects with congenital antithrombin deficiency and in women using oral contraceptives. In deep vein thrombosis (phlebographically confirmed), it is increased by 29.4% (extrinsic) and 53% (intrinsic). In (angiographically assessed) coronary artery disease the increase is by 10% and 17% respectively.
Wielders et al. (Wed,) reported a other. No clinical study data is present in the provided text, which consists only of journal editorial board information.